Archive: Company News
Company News: Aleva Neurotherapeutics Recruits First Patient into its PMCF Study with its directSTIM™ Directional Deep Brain Stimulation System
— First system implanted at University Hospital of Dresden / Prof. Sobottka
— Post-market clinical follow-up and revenue-generating study in the EU
— Targeting US FDA IDE approval in Q4, 2021
Aleva Neurotherapeutics, a leading developer of implants for deep brain stimulation (DBS) in major neurological indications such as Parkinson’s disease and essential tremor, today announced the successful implantation of a first patient with the directSTIMTM Directional Deep Brain Stimulation System.
Science Translational Medicine Publication: Innovative Molecules´ Drug Candidate Affects Recurrent Herpes Simplex Virus Infections
— IM-250 reduces viral load, viral shedding and recurrence rate
— Potential treatment for persistent, neurotrophic herpes simplex
Innovative Molecules GmbH, a drug development company focused on developing next-generation treatments for Herpes simplex-induced diseases, today announced preclinical data demonstrating that the Company’s drug candidate IM-250 affects acute as well as chronic neural Herpes simplex virus (HSV) infections in mice and guinea pigs. IM-250 is a proprietary, novel helicase-primase inhibitor.
Company News: Innovative Molecules raises €20 million Series A equity financing round
— Proceeds dedicated to advance Herpes simplex treatment IM-250 to Phase II
— IM-250 demonstrates unprecedented impact on viral reservoir in preclinical studies
Innovative Molecules GmbH, a German, Munich-based drug development company focused on developing next-generation treatments for Herpes simplex-induced diseases, today announced the closing of its €20 million Series A equity financing round led by LSP (Life Sciences Partners).
Company News: Patients with Risk Factors Benefit from Using COPAL® G+C from Heraeus Medical in Arthroplasty Procedures
– New studies reveal benefits of dual antibiotic-loaded bone cement (COPAL® G+C) to reduce periprosthetic joint infections in risk for infection patients
– 34% reduction of infection risk for primary procedures
– 57% reduction of infection risk for aseptic knee revisions
Patients at risk of infection benefit from bone cement with a combination of antibiotics
COPAL® G+C bone cement containing two antibiotics has long been used for revisions after replacement of hip or knee joints.